Emcure Pharmaceuticals announced the appointment of Mr. C. S. Muralidharan as an Additional Director (Non-Executive and Independent) on its Board, effective from April 01, 2026. This appointment, based on the Nomination and Remuneration Committee’s recommendation, is for an initial term of three consecutive years, pending shareholder approval. Mr. Muralidharan brings extensive experience across the hydrocarbon and pharmaceutical sectors to the role.
Board Enhancement: Appointment of New Director
Emcure Pharmaceuticals Limited has approved the appointment of Mr. C. S. Muralidharan (DIN: 00014740) as an Additional Director, designated as Non-Executive and Independent. The Board of Directors finalized this decision during its meeting held on Monday, March 09, 2026.
Effective Date and Tenure
The appointment will take effect from April 01, 2026. Mr. Muralidharan will serve as an Independent Director for an initial term comprising three (3) consecutive years, also commencing on April 01, 2026. This appointment is subject to subsequent approval by the Members of the Company.
Director Independence Confirmation
The Company confirms that Mr. C. S. Muralidharan is not currently debarred from holding a Director’s office by any regulatory authority. Furthermore, he is explicitly not related to any existing Director(s) or Key Managerial Personnel(s) of Emcure Pharmaceuticals.
Profile and Expertise of Mr. Muralidharan
Mr. C. S. Muralidharan possesses over 40 years of corporate experience, spanning the hydrocarbon and pharmaceutical industries. His leadership roles have involved significant work across various entities in India, Asia, and Europe. His expertise encompasses Strategy & M&A transactions, enterprise risk management, capital restructuring, enterprise transformation, and ESG initiatives.
Previously, he held roles with organizations including Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, and Watson Group. In his last role, he was associated with Sun Pharmaceutical Industries Limited as Group Chief Financial Officer, where he managed global finance strategy, M&A, investor relations, governance, and compliance.
Academically, Mr. Muralidharan is a Cost & Management Accountant and completed the Executive Program in General Management from the Booth School of Business, University of Chicago.
Meeting Details
The Board meeting where this resolution was passed commenced at 12:15 p.m. (IST) and concluded at 12:40 p.m. (IST) on March 09, 2026.
Source: BSE
